HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
De novo frameshift mutation in fibroblast growth factor 8 in a male patient with gonadotropin deficiency.
|
24280688 |
2014 |
HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
DLX5, FGF8 and the Pin1 isomerase control ΔNp63α protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations.
|
24569166 |
2014 |
HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA
|
0.600 |
GeneticVariation
|
disease |
CLINVAR |
Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes.
|
23533228 |
2013 |
HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism.
|
23643382 |
2013 |
HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Nonsense mutations in FGF8 gene causing different degrees of human gonadotropin-releasing deficiency.
|
20463092 |
2010 |
HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice.
|
18596921 |
2008 |
HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice.
|
18596921 |
2008 |
HYPOGONADOTROPIC HYPOGONADISM 6 WITH OR WITHOUT ANOSMIA
|
0.600 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Kallmann Syndrome
|
0.560 |
Biomarker
|
disease |
BEFREE |
Indeed, FGF8 and FGFR1 deficiency severely compromises vertebrate reproduction in mice and humans and is associated with Kallmann Syndrome (KS), a congenital disease characterized by hypogonadotropic hypogonadism associated with anosmia.
|
31361780 |
2019 |
Kallmann Syndrome
|
0.560 |
Biomarker
|
disease |
BEFREE |
In Kallmann syndrome (KS), according to the presence of certain accompanying clinical features, genetic screening for particular gene(s) may be prioritized: synkinesia (KAL1), dental agenesis (FGF8/FGFR1), bony anomalies (FGF8/FGFR1), and hearing loss (CHD7, SOX10).
|
26680571 |
2016 |
Kallmann Syndrome
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
Both our patients had additional bilateral cryptorchidism, a key phenotypic feature in males with FGF8 associated Kallmann syndrome.Each mutation was paternally inherited.
|
25131394 |
2014 |
Kallmann Syndrome
|
0.560 |
Biomarker
|
disease |
BEFREE |
To date, five genes for KS have been identified: KAL1, located on the X chromosome, and FGFR1, PROKR2, PROK2 and FGF8, which are involved in autosomally transmitted forms of KS.
|
20536592 |
2010 |
Kallmann Syndrome
|
0.560 |
Biomarker
|
disease |
BEFREE |
Finally, recent additional observations, notably using animal models, but also the description of human mutations in a specific ligand of FGFR1, FGF8, are beginning to shed light on the pathogenesis of GnRH deficiency in general, not just KS.
|
20389085 |
2010 |
Kallmann Syndrome
|
0.560 |
GermlineCausalMutation
|
disease |
ORPHANET |
Nonsense mutations in FGF8 gene causing different degrees of human gonadotropin-releasing deficiency.
|
20463092 |
2010 |
Kallmann Syndrome
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
Substantial variation in clinical expression, from complete anosmia and hypogonadotropic hypogonadism to delayed puberty and normosmia, of the same Kallmann syndrome gene defects including in newer ones (FGF8 and CHD7) continues to be repeatedly observed.
|
20543690 |
2010 |
Kallmann Syndrome
|
0.560 |
GermlineCausalMutation
|
disease |
ORPHANET |
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice.
|
18596921 |
2008 |
Kallmann Syndrome
|
0.560 |
Biomarker
|
disease |
CTD_human |
|
|
|
DiGeorge Syndrome
|
0.500 |
Biomarker
|
disease |
CTD_human |
Dose-dependent interaction of Tbx1 and Crkl and locally aberrant RA signaling in a model of del22q11 syndrome.
|
16399080 |
2006 |
DiGeorge Syndrome
|
0.500 |
Biomarker
|
disease |
MGD |
|
|
|
Holoprosencephaly
|
0.450 |
GeneticVariation
|
disease |
BEFREE |
Loss-of-function mutations in FGF8 can be independent risk factors for holoprosencephaly.
|
29584859 |
2018 |
Holoprosencephaly
|
0.450 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutational Spectrum in Holoprosencephaly Shows That FGF is a New Major Signaling Pathway.
|
27363716 |
2016 |
Holoprosencephaly
|
0.450 |
AlteredExpression
|
disease |
BEFREE |
Finally, to analyze the mechanisms of holoprosencephaly observed in the case described here, we include a concise review on the current understanding of how FGFs and their receptors are expressed in the rostral signaling center (particularly Fgf8).
|
21204232 |
2011 |
Holoprosencephaly
|
0.450 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to screen for FGF8 mutations in patients with septo-optic dysplasia (n = 374) or holoprosencephaly (HPE)/midline clefts (n = 47).
|
21832120 |
2011 |
Holoprosencephaly
|
0.450 |
Biomarker
|
disease |
BEFREE |
In our study we prospectively analyzed a small cohort of 10 patients in whom we identified mutations in SHH, SIX3, ZIC2, or FGF8, the latter of which is a very recently described HPE-associated gene.
|
21976454 |
2011 |
Holoprosencephaly
|
0.450 |
GeneticVariation
|
disease |
BEFREE |
Frank holoprosencephaly was present in 11 individuals with deletions of one of the common HPE genes SHH, ZIC2, SIX3, and TGIF1, in one individual with a deletion of the HPE8 locus at 14q13, and in one individual with a deletion of FGF8, whereas deletions of other HPE loci and candidate genes (FOXA2 and LRP2) expressed microforms of HPE.
|
20066439 |
2010 |